"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

The biotech company’s revenue halved in 2024, and it continues to face uncertainty in the vaccine market. Biotech giant ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...

CEO Stéphane Bancel on Friday stated that the company is lowering its annual revenue forecast due to the timing of shipments despite the company’s upbeat second-quarter numbers. The vaccine maker ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as ...

The Cambridge-based vaccine maker, which became a household name during the pandemic, is cutting its global workforce to ...

Vaccine manufacturer Moderna will lay off hundreds of employees about five years after it rose to prominence during the COVID-19 pandemic. The layoffs make up about 10% of Moderna's global workforce, ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

After another year of transformational revenue from the company's COVID-19 vaccine, Moderna has rewarded CEO Stéphane Bancel with a pay package of $19.4 million, according to a proxy statement ...

Adam Glanzman/Bloomberg I t’s been a whirlwind year for Stéphane Bancel. Just over a year ago in March 2020, the World Health Organization declared the Covid-19 outbreak a pandemic.